Advances in the management of KRAS-mutant NSCLC

Jorge Nieva, MD, University of California, San Francisco, CA, talks on the latest developments in the treatment of KRAS-mutant non-small cell lung cancer (NSCLC). Targeting specific mutations is necessary to produce safe and efficacious targeted therapies, and G12C is currently the only targetable mutation. Immunotherapy remains the preferred front-line therapy for KRAS-mutant NSCLC. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.